Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that new data from the Phase 1/2 clinical trial for IMO-8400, a TLR 7,8 and 9 antagonist, being evaluated for the treatment of relapsed, refractory patients suffering from Waldenström’s Macroglobulinemia, will be presented at the 2015 American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 5-8, 2015.
The open-label, dose-ranging clinical trial included three dose-escalating cohorts on IMO-8400 and enrolled 19 patients, who were relapsed or refractory to prior therapies. Data from these 19 patients will be presented at the ASH Meeting.
“The presentation of the clinical safety and efficacy data from our IMO-8400 study in Waldenström’s Macroglobulinemia is a positive step forward for our company, for our clinical aspirations in cancer care and for the role of Toll-Like Receptors as a therapeutic option for patients suffering from B-cell Lymphomas,” stated Vincent Milano, Idera’s Chief Executive Officer. “We look forward to presenting the data next month at the ASH conference and beginning to elucidate the path forward forIMO-8400 beyond this first clinical study.” (Original Source)
Shares of Idera Pharmaceuticals closed yesterday at $3.29. IDRA has a 1-year high of $5.48 and a 1-year low of $2.27. The stock’s 50-day moving average is $3.15 and its 200-day moving average is $3.23.
Idera Pharmaceuticals Inc is a clinical stage biotechnology company. The Company is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases.